Financials data is unavailable for this security.
View more
Year on year Novo Nordisk A/S grew revenues 31.26% from 176.95bn to 232.26bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 50.71% net income growth from 55.53bn to 83.68bn.
Gross margin | 84.65% |
---|---|
Net profit margin | 36.55% |
Operating margin | 44.80% |
Return on assets | 32.53% |
---|---|
Return on equity | 99.87% |
Return on investment | 71.03% |
More ▼
Cash flow in DKKView more
In 2023, Novo Nordisk A/S increased its cash reserves by 13.74%, or 1.74bn. The company earned 108.91bn from its operations for a Cash Flow Margin of 46.89%. In addition the company used 43.89bn on investing activities and also paid 63.16bn in financing cash flows.
Cash flow per share | 21.80 |
---|---|
Price/Cash flow per share | 32.01 |
Book value per share | 22.19 |
---|---|
Tangible book value per share | 8.81 |
More ▼
Balance sheet in DKKView more
Current ratio | 0.703 |
---|---|
Quick ratio | 0.5001 |
Total debt/total equity | 0.2722 |
---|---|
Total debt/total capital | 0.214 |
More ▼
Growth rates in DKK
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 51.61% and 52.38%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg) | 1.68% |
---|---|
Div growth rate (5 year) | 18.20% |
Payout ratio (TTM) | 47.03% |
EPS growth(5 years) | 18.50 |
---|---|
EPS (TTM) vs TTM 1 year ago | 48.15 |
More ▼